🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Ascentage Pharma Group clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China, USA, UK and India registers with Ascentage Pharma Group as lead sponsor. Synced 26 Sep 2026
26Current trials
23Recruiting now
15Drugs in these trials
4Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Ascentage Pharma Group is the lead sponsor of 26 current clinical trials in our China, USA, UK and India registers. 23 are recruiting patients now. The most common phase is Phase 1. The drugs named most often in its trials are Lisaftoclax, Olverembatinib and APG-115. The most-studied condition is CLL/SLL.

ClinicalTrials.gov trials by status

  • Recruiting2388%
  • Active, closed312%

Trials by phase

  • Phase 11142%
  • Phase 3727%
  • Phase 1/2623%
  • Phase 228%
01

Clinical trials sponsored by Ascentage Pharma Group

26 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Global Trial in APG2575 for Patients With CLL/SLL
NCT06104566 · CLL/SLL
Phase 3 Recruiting 2023-12 UK, USA, India, China
Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
NCT04501120 · ClinicalTrials.gov ↗ · Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy
Phase 1/2 Recruiting 2020-09 China
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
NCT04260022 · Leukemia, Myeloid, Chronic, Myeloid Leukemia, Chronic Myeloid Leukemia
Phase 1 Recruiting 2020-01 USA
Study of Olverembatinib (HQP1351) in Patients With CML-CP
NCT06423911 · ClinicalTrials.gov ↗ · Chronic Myeloid Leukemia, CML, CML, Chronic Phase
Phase 3 Recruiting 2024-02 UK, USA, India
APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST
NCT06687070 · ClinicalTrials.gov ↗ · Platinum-resistant Recurrent Ovarian Cancer, Advanced Solid Tumor
Drug: APG -2449
Phase 1 Recruiting 2024-12 China
APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors
NCT04785196 · ClinicalTrials.gov ↗ · Liposarcoma, Advanced Solid Tumor
Phase 1/2 Recruiting 2021-05 China
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
NCT06051409 · ClinicalTrials.gov ↗ · Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Phase 3 Recruiting 2023-08 UK, USA, China
Pharmacokinetics of Olverembatinib in Participants With Hepatic Impairment
NCT07282093 · ClinicalTrials.gov ↗ · Pharmacokinetic, Olverembatinib
Phase 1 Recruiting 2025-11 China
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
NCT07424833 · ClinicalTrials.gov ↗ · Relapsed/Refractory Hematological Malignancies, Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL, Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL; Including Richter Transformation)
Phase 1 Recruiting 2026-08 USA, China
A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of APG-5918.
NCT05773586 · ClinicalTrials.gov ↗ · Anemia
Phase 1 Recruiting 2023-03 China
APG-2449 in Patients With Advanced Solid Tumors
NCT03917043 · ClinicalTrials.gov ↗ · Advanced Solid Cancer, Non Small Cell Lung Cancer, Esophageal Cancer
Drug: APG -2449
Phase 1 Recruiting 2019-05 China
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
NCT04496349 · ClinicalTrials.gov ↗ · T-Prolymphocytic Leukemia, Non-Hodgkins Lymphoma
Phase 2 Recruiting 2021-07 USA
Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
NCT06641414 · ClinicalTrials.gov ↗ · Higher-risk Myelodysplastic Syndrome
Phase 3 Recruiting 2025-01 USA, China
A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia
NCT06389292 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia
Phase 3 Recruiting 2024-06 China
Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL
NCT04215809 · ClinicalTrials.gov ↗ · CLL/SLL
Phase 1 Recruiting 2020-03 USA
Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
NCT05147467 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Phase 2 Recruiting 2021-12 China
Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
NCT04494503 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Phase 1/2 Recruiting 2020-08 China
A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.
NCT04275518 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
Phase 1 Recruiting 2020-07 China
A Study of HQP1351 in Patients With GIST or Other Solid Tumors
NCT03594422 · ClinicalTrials.gov ↗ · Gastrointestinal Stromal Tumor (GIST), Solid Tumor, Adult
Phase 1 Recruiting 2018-07 China
A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.
NCT06319456 · ClinicalTrials.gov ↗ · CLL/SLL
Phase 3 Recruiting 2024-04 China
A Study of Olverembatinib in SDH-deficient GIST.
NCT06640361 · ClinicalTrials.gov ↗ · GIST
Phase 3 Recruiting 2024-11 China
APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors
NCT05701306 · ClinicalTrials.gov ↗ · Neuroblastoma, Solid Tumor
Phase 1/2 Recruiting 2023-02 China
A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.
NCT06182969 · ClinicalTrials.gov ↗ · SLE
Phase 1/2 Recruiting 2024-08 China
A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
NCT03611868 · ClinicalTrials.gov ↗ · Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma, Uveal Melanoma
Phase 1/2 Active, closed 2018-08 USA
A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients
NCT04001777 · ClinicalTrials.gov ↗ · EGFR Positive Non-small Cell Lung Cancer
Phase 1 Active, closed 2019-07 China
A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies
NCT03913949 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
Phase 1 Active, closed 2019-06 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Ascentage Pharma Group trials

15 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Ascentage Pharma Group trials

45 conditions
CLL/SLL3Chronic Lymphocytic Leukemia3Chronic Myeloid Leukemia2Advanced Solid Tumor2Small Lymphocytic Lymphoma2CML1CML, Chronic Phase1Ph+ ALL1Leukemia, Lymphoblastic, Acute, Philadelphia-Positive1Leukemia, Myeloid, Chronic1Myeloid Leukemia1Philadelphia Positive Acute Lymphoblastic Leukemia1Unresectable or Metastatic Melanoma or Advanced Solid Tumors1Melanoma1Uveal Melanoma1P53 Mutation1T-Prolymphocytic Leukemia1Non-Hodgkins Lymphoma1Higher-risk Myelodysplastic Syndrome1Relapsed/Refractory Hematological Malignancies1Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL1Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL; Including Richter Transformation)1Relapsed/Refractory Mantle Cell Lymphoma (MCL)1Relapsed/Refractory Acute Myeloid Leukaemia1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China2119
Clinical trials in USA98
Clinical trials in UK33
Clinical trials in India22

A trial with sites in more than one country appears in each of those registers.

05

Questions about Ascentage Pharma Group trials

How many clinical trials does Ascentage Pharma Group sponsor?

Ascentage Pharma Group is the lead sponsor of 26 current trials on ClinicalTrials.gov in our China, USA, UK and India registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Ascentage Pharma Group trials recruiting?

Yes. 23 of its 26 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Ascentage Pharma Group testing?

Its current trials name 15 drugs and biologicals as interventions. The most frequent are Lisaftoclax (10), Olverembatinib (4), APG-115 (3), Azacitidine (3) and APG -2449 (2). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.